References
- Baker EA, Leaper DJ (2003). The plasminogen activator and matrix metalloproteinase systems in colorectal cancer: relationship to tumour pathology. Eur J Cancer, 39, 981-8. https://doi.org/10.1016/S0959-8049(03)00065-0
- Battle A, Khan Z, Wang SH, et al (2015). Genomic variation. Impact of regulatory variation from RNA to protein. Science, 347, 664-7. https://doi.org/10.1126/science.1260793
- Behrens P, Rothe M, Wellmann A, et al (2001). The Ets-1 transcription factor is up-regulated together with MMP 1 and MMP 9 in the stroma of pre-invasive breast cancer. J Pathol, 194, 43-50. https://doi.org/10.1002/path.844
- Choi IS, Wu TT (2005). Epigenetic alterations in gastric carcinogenesis. Cell Res, 15, 247-54. https://doi.org/10.1038/sj.cr.7290293
- Crew KD, Neugut AI (2006). Epidemiology of gastric cancer. World J Gastroenterol, 12, 354-62. https://doi.org/10.3748/wjg.v12.i3.354
- Dikshit RP, Mathur G, Mhatre S, et al (2011). Epidemiological review of gastric cancer in India. Indian J Med Paediatr Oncol, 32, 3-11. https://doi.org/10.4103/0971-5851.81883
- Fanjul-Fernandez M, Folgueras AR, Cabrera S, et al (2010). Matrix metalloproteinases: Evolution, gene regulation and functional analysis in mouse models. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1803, 3-19. https://doi.org/10.1016/j.bbamcr.2009.07.004
- Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917. https://doi.org/10.1002/ijc.25516
- Forget MA, Desrosiers RR, Beliveau R (1999). Physiological roles of matrix metalloproteinases: implications for tumor growth and metastasis. Can J Physiol Pharmacol, 77, 465-80. https://doi.org/10.1139/y99-055
- Fox JG, Wang TC (2007). Inflammation, atrophy, and gastric cancer. J Clin Invest, 117, 60-9. https://doi.org/10.1172/JCI30111
- Ghilardi G, Biondi ML, Mangoni J, et al (2001). Matrix metalloproteinase-1 promoter polymorphism 1G/2G is correlated with colorectal cancer invasiveness. Clin Cancer Res, 7, 2344-6.
- Gum R, Lengyel E, Juarez J, et al (1996). Stimulation of 92-kDa gelatinase B promoter activity by ras is mitogen-activated protein kinase kinase 1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP-1 sequences. J Biol Chem, 271, 10672-80. https://doi.org/10.1074/jbc.271.18.10672
- Hannenhalli S (2008). Eukaryotic transcription factor binding sites--modeling and integrative search methods. Bioinformatics, 24, 1325-31. https://doi.org/10.1093/bioinformatics/btn198
- Hellmig S, Ott S, Rosenstiel P, et al (2006). Genetic variants in matrix metalloproteinase genes are associated with development of gastric ulcer in H. Pylori infection. Am J Gastroenterol, 101, 29-35. https://doi.org/10.1111/j.1572-0241.2005.00348.x
- Hirakawa S, Lange EM, Colicigno CJ, et al (2003). Evaluation of genetic variation and association in the matrix metalloproteinase 9 (MMP9) gene in ESRD patients. Am J Kidney Dis, 42, 133-42. https://doi.org/10.1016/S0272-6386(03)00416-5
- Honda M, Mori M, Ueo H, et al (1996). Matrix metalloproteinase-7 expression in gastric carcinoma. Gut, 39, 444-8. https://doi.org/10.1136/gut.39.3.444
- Hu Z, Huo X, Lu D, et al (2005). Functional polymorphisms of matrix metalloproteinase-9 are associated with risk of occurrence and metastasis of lung cancer. Clin Cancer Res, 11, 5433-9. https://doi.org/10.1158/1078-0432.CCR-05-0311
- Inoue T, Yashiro M, Nishimura S, et al (1999). Matrix metalloproteinase-1 expression is a prognostic factor for patients with advanced gastric cancer. Int J Mol Med, 4, 73-7.
- Inuzuka K, Ogata Y, Nagase H, et al (2000). Significance of coexpression of urokinase-type plasminogen activator, and matrix metalloproteinase 3 (stromelysin) and 9 (gelatinase B) in colorectal carcinoma. J Surg Res, 93, 211-8. https://doi.org/10.1006/jsre.2000.5952
- Joos L, He JQ, Shepherdson MB, et al (2002). The role of matrix metalloproteinase polymorphisms in the rate of decline in lung function. Hum Mol Genet, 11, 569-76. https://doi.org/10.1093/hmg/11.5.569
- Kallakury BV, Karikehalli S, Haholu A, et al (2001). Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res, 7, 3113-9.
- Kanamori Y, Matsushima M, Minaguchi T, et al (1999). Correlation between expression of the matrix metalloproteinase-1 gene in ovarian cancers and an insertion/deletion polymorphism in its promoter region. Cancer Res, 59, 4225-7.
- Kim JH, Pyun JA, Lee KJ, et al (2011). [Study on association between single nucleotide polymorphisms of MMP7, MMP8, MMP9 genes and development of gastric cancer and lymph node metastasis]. Korean J Gastroenterol, 58, 245-51. https://doi.org/10.4166/kjg.2011.58.5.245
- Kohn EC, Liotta LA (1995). Molecular insights into cancer invasion: strategies for prevention and intervention. Cancer Res, 55, 1856-62.
- Kubben FJ, Sier CF, Meijer MJ, et al (2006). Clinical impact of MMP and TIMP gene polymorphisms in gastric cancer. Br J Cancer, 95, 744-51. https://doi.org/10.1038/sj.bjc.6603307
- Kundu P, Mukhopadhyay AK, Patra R, et al (2006). Cag pathogenicity island-independent up-regulation of matrix metalloproteinases-9 and -2 secretion and expression in mice by Helicobacter pylori infection. J Biol Chem, 281, 34651-62. https://doi.org/10.1074/jbc.M604574200
- Langers AM, Verspaget HW, Hommes DW, et al (2011). Singlenucleotide polymorphisms of matrix metalloproteinases and their inhibitors in gastrointestinal cancer. World J Gastrointest Oncol, 3, 79-98. https://doi.org/10.4251/wjgo.v3.i6.79
- Lee SH, Han SK, Shim YS, et al (2009). Effect of matrix metalloproteinase-9 -1562C/T gene polymorphism on manifestations of pulmonary tuberculosis. Tuberculosis (Edinb), 89, 68-70. https://doi.org/10.1016/j.tube.2008.08.001
- Lee TY, Yu CC, Wu CC, et al (2013). MMP-9 -1562 Promoter Polymorphism Associated with Gastric Cancer Risk in Females. Hepatogastroenterology, 60.
- Libermann TA, Zerbini LF (2006). Targeting transcription factors for cancer gene therapy. Curr Gene Ther, 6, 17-33. https://doi.org/10.2174/156652306775515501
- Maeda S, Haneda M, Guo B, et al (2001). Dinucleotide repeat polymorphism of matrix metalloproteinase-9 gene is associated with diabetic nephropathy. Kidney Int, 60, 1428-34. https://doi.org/10.1046/j.1523-1755.2001.00945.x
- Matsumura S, Oue N, Nakayama H, et al (2005). A single nucleotide polymorphism in the MMP-9 promoter affects tumor progression and invasive phenotype of gastric cancer. J Cancer Res Clin Oncol, 131, 19-25. https://doi.org/10.1007/s00432-004-0621-4
- McDonnell S, Matrisian LM (1990). Stromelysin in tumor progression and metastasis. Cancer Metastasis Rev, 9, 305-19. https://doi.org/10.1007/BF00049521
- Murthy NS, Chaudhry K, Rath GK (2008). Burden of cancer and projections for 2016, Indian scenario: gaps in the availability of radiotherapy treatment facilities. Asian Pac J Cancer Prev, 9, 671-7.
- Nakayama T, Ito M, Ohtsuru A, et al (1996). Expression of the Ets-1 proto-oncogene in human gastric carcinoma: correlation with tumor invasion. Am J Pathol, 149, 1931-9.
- Nomura H, Sato H, Seiki M, et al (1995). Expression of membrane-type matrix metalloproteinase in human gastric carcinomas. Cancer Res, 55, 3263-6.
- Ozalp S, Tanir HM, Yalcin OT, et al (2003). Prognostic value of matrix metalloproteinase-9 (gelatinase-B) expression in epithelial ovarian tumors. Eur J Gynaecol Oncol, 24, 417-20.
- Pinto LA, Depner M, Klopp N, et al (2010). MMP-9 gene variants increase the risk for non-atopic asthma in children. Respir Res, 11, 23. https://doi.org/10.1186/1465-9921-11-23
- Sakata K, Satoh M, Someya M, et al (2004). Expression of matrix metalloproteinase 9 is a prognostic factor in patients with non-Hodgkin lymphoma. Cancer, 100, 356-65. https://doi.org/10.1002/cncr.11905
- Sentani K, Oue N, Sakamoto N, et al (2008). Gene expression profiling with microarray and SAGE identifies PLUNC as a marker for hepatoid adenocarcinoma of the stomach. Mod Pathol, 21, 464-75. https://doi.org/10.1038/modpathol.3801050
- Shimajiri S, Arima N, Tanimoto A, et al (1999). Shortened microsatellite d(CA)21 sequence down-regulates promoter activity of matrix metalloproteinase 9 gene. FEBS Lett, 455, 70-4. https://doi.org/10.1016/S0014-5793(99)00863-7
- Sier CF, Kubben FJ, Ganesh S, et al (1996). Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer, 74, 413-7. https://doi.org/10.1038/bjc.1996.374
- Sternlicht MD, Werb Z (2001). How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol, 17, 463-516. https://doi.org/10.1146/annurev.cellbio.17.1.463
- Swarnakar S, Ganguly K, Kundu P, et al (2005). Curcumin regulates expression and activity of matrix metalloproteinases 9 and 2 during prevention and healing of indomethacininduced gastric ulcer. J Biol Chem, 280, 9409-15. https://doi.org/10.1074/jbc.M413398200
- Tan SY, Wang JY, Shen L, et al (2007). Relationship between preoperative staging by endoscopic ultrasonography and MMP-9 expression in gastric carcinoma. World J Gastroenterol, 13, 2108-12. https://doi.org/10.3748/wjg.v13.i14.2108
- Tang Y, Zhu J, Chen L, et al (2008). Associations of matrix metalloproteinase-9 protein polymorphisms with lymph node metastasis but not invasion of gastric cancer. Clin Cancer Res, 14, 2870-7. https://doi.org/10.1158/1078-0432.CCR-07-4042
- Tanioka Y, Yoshida T, Yagawa T, et al (2003). Matrix metalloproteinase-7 and matrix metalloproteinase-9 are associated with unfavourable prognosis in superficial oesophageal cancer. Br J Cancer, 89, 2116-21. https://doi.org/10.1038/sj.bjc.6601372
- Venkateshwari A, Sri Manjari K, Krishnaveni D, et al (2011). Role of Plasma MMP 9 levels in the pathogenesis of chronic pancreatitis. Indian J Clin Biochem, 26, 136-9. https://doi.org/10.1007/s12291-010-0103-1
- Woo M, Park K, Nam J, et al (2007). Clinical implications of matrix metalloproteinase-1, -3, -7, -9, -12, and plasminogen activator inhibitor-1 gene polymorphisms in colorectal cancer. J Gastroenterol Hepatol, 22, 1064-70. https://doi.org/10.1111/j.1440-1746.2006.04424.x
- Wu CW, Chi CW, Lin WC (2002). Gastric cancer: prognostic and diagnostic advances. Expert Rev Mol Med, 4, 1-12.
- Xing LL, Wang ZN, Jiang L, et al (2007). Matrix metalloproteinase-9-1562C>T polymorphism may increase the risk of lymphatic metastasis of colorectal cancer. World J Gastroenterol, 13, 4626-9. https://doi.org/10.3748/wjg.v13.i34.4626
- Ye S, Eriksson P, Hamsten A, et al (1996). Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. J Biol Chem, 271, 13055-60. https://doi.org/10.1074/jbc.271.22.13055
- Zhang B, Ye S, Herrmann SM, et al (1999). Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation, 99, 1788-94. https://doi.org/10.1161/01.CIR.99.14.1788
- Zhang J, Jin X, Fang S, et al (2004a). The functional SNP in the matrix metalloproteinase-3 promoter modifies susceptibility and lymphatic metastasis in esophageal squamous cell carcinoma but not in gastric cardiac adenocarcinoma. Carcinogenesis, 25, 2519-24. https://doi.org/10.1093/carcin/bgh269
- Zhang QW, Liu L, Chen R, et al (2012). Matrix metalloproteinase-9 as a prognostic factor in gastric cancer: a meta-analysis. Asian Pac J Cancer Prev, 13, 2903-8. https://doi.org/10.7314/APJCP.2012.13.6.2903
- Zhang S, Li L, Lin JY, et al (2003). Imbalance between expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in invasiveness and metastasis of human gastric carcinoma. World J Gastroenterol, 9, 899-904. https://doi.org/10.3748/wjg.v9.i5.899
- Zhang XM, Miao XP, Xiong P, et al (2004b). [Association of functional polymorphisms in matrix metalloproteinase-2 (MMP-2) and MMP-9 genes with risk of gastric cancer in a Chinese population]. Ai Zheng, 23, 1233-7.
Cited by
- Tspan9 inhibits the proliferation, migration and invasion of human gastric cancer SGC7901 cells via the ERK1/2 pathway vol.36, pp.1, 2016, https://doi.org/10.3892/or.2016.4805
- [6]-Gingerol enhances the cisplatin sensitivity of gastric cancer cells through inhibition of proliferation and invasion via PI3K/AKT signaling pathway pp.0951418X, 2019, https://doi.org/10.1002/ptr.6325